TrialGynecologic oncology2024

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

Melissa Lumish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.